Tag: Zepbound
Health Canada approves Zepbound for OSA
June 17, 2026HME News Staff
TORONTO – Health Canada has approved Eli Lilly Canada’s Zepbound for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity in combination with a reduced-calorie diet and increased physical activity. Lilly says Zepbound is the first medication approved in Canada for this indication, offering a new option for people living with a sleep-related breathing disorder closely linked with obesity. “Zepbound's approval for the treatment of obstructive...
Zepbound, Shaq launch national OSA awareness campaign
June 10, 2026HME News Staff
INDIANAPOLIS – Eli Lilly and Company has announced that basketball legend and cultural icon Shaquille O'Neal is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight into his diagnosis and treatment journey with Zepbound (tirzepatide). After years of dismissing fatigue, loud snoring and difficulty focusing as normal parts of his life, O'Neal learned they were actually symptoms of moderate-to-severe OSA. Moderate-to-severe OSA is a serious...
FDA approves GLP-1 for OSA
December 23, 2024HME News Staff
WASHINGTON – The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used in combination with a reduced-calorie diet and increased physical activity.
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical...